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OBJECTIVES: To describe the impact of best tumor response to therapy (Complete 
Response [CR], Partial Response [PR], and Minimal Response [MR]) on HRQoL 
using the European Organization for Research and Treatment of Cancer (EORTC) 
QLQ-C30 scores. METHODS: The VISTA trial was a randomized, open-label, mul-
ticentre study designed to compare the efﬁcacy and safety of V-MP to melphalan/pred-
nisone (MP) in subjects with previously untreated multiple myeloma. Patients were 
followed over a 9 cycle period (54 weeks) and for a post-treatment follow-up phase. 
Response to therapy was deﬁned according to the European group for Blood and 
Marrow Transplant criteria. The EORTC QLQ-C30, a HRQoL questionnaire com-
monly used in multiple myeloma, was administered at screening, day 1 of each cycle 
and every 8 weeks until progression during follow-up. Change in HRQoL scores from 
best response were analyzed by response (CR, MR or PR). RESULTS: By 3 cycles 
after best response, CR patients of the V-MP arm experienced an average, clinically-
relevant (5 point or more; Dubois et al, JCO 2006; 24:976–82) improvement in 
“Physical Functioning” (n  63); this beneﬁt was delayed for PR patients and rarely 
occurred for MR patients. A similar pattern was found for “Pain”; for CR patients 
the mean, clinically relevant improvement was reached after 3 cycles in the V-MP arm 
(n  62). At 4 cycles after CR onset, the improvement in all the EORTC QLQ-C30 
scores in the V-MP arm (n  53–55) except “Cognitive Functioning”, “Diarrhea” and 
“Financial problems”, was greater than 5 points. CONCLUSIONS: Overall, CR pro-
duced improvement in patient-reported HRQoL but gains were also observed with 
PR. MR was infrequently and inconsistently associated with HRQoL beneﬁts. These 
results could not be reliably replicated in the MP arm because of the few patients in 
the CR group. Also results were limited by the short follow-up period after achieving 
best response.
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OBJECTIVES: Collection and analysis of quality of life (QoL) data is complex in 
patients with metastatic breast cancer (mBC) as missing values are often associated 
with worsened QoL, progressive disease (PD) or death. Nonetheless, it is a relevant 
endpoint when assessing therapeutic options in mBC. Proper interpretation of data 
requires sensitivity analyses with different imputation rules for missing data to avoid 
bias. We compare protocol-speciﬁed analysis (no imputation) on QoL in the AVADO 
trial with two imputation strategies. METHODS: Patients (n  736) were randomised 
to docetaxel (doc) plus either placebo (control) or bevacizumab (Bv) 7.5 or 15 mg/kg. 
The self-assessed Functional Assessment of Cancer Therapy-Breast (FACT-B [FACT-
GBCS]) questionnaire was administered at pre-deﬁned timepoints. QoL data were 
analysed according-to-protocol (no imputation), by imputation rule 1 (missing data 
for PD set to zero [favours treatment arm]) and imputation rule 2 (missing data for 
PD replaced with last value carried forward [favours control arm]). Missing values 
due to death were set to zero for both imputation rules. RESULTS: QoL assessments 
were completed at baseline and weeks 9, 15 and 33 (after chemotherapy completed), 
in 656, 570, 510 and 289 patients, respectively. Compared with baseline, mean changes 
with no imputation were near zero or better for both docBv doses, and were consis-
tently worse for control. Applying imputation rules 1 and 2 gave consistent deteriora-
tion of mean values for all arms; however, compared with control, both docBv arms 
reported statistically signiﬁcant better scores (p  0.05) at most evaluation timepoints. 
At week 9, docBv7.5 reported a signiﬁcant difference with both rules (two extremes). 
CONCLUSIONS: Sensitivity analysis using different imputation rules to account 
for missing values is an important exercise to understand accurately the potential 
QoL beneﬁt of a cancer therapy. This sensitivity analysis suggests that patients receiving 
docBv may have a signiﬁcant QoL beneﬁt compared with control group.
PCN142
EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH  
NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE 
CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES
Vargas J1, Gomez Rangel JD2, Martínez-Barrera L3, Mendoza D3, Paladio Á4
1Econopharma Consulting SA de CV, Mexico, DF, Mexico, 2Centro Médico Nacional Siglo 
XXI. Hospital de Oncología, Mexico, Mexico, 3Instituto Nacional de Enfermedades 
Respiratorias, Mexico, Mexico, 4Econopharma Consulting SA de CV, Mexico City, Mexico
OBJECTIVES: The aim of this study is to evaluate in a descriptive way the self-
informed quality of life in a group of patients with Non-Small Cell Lung Cancer who 
previously failed to chemotherapy and currently are treated with Erlotinib vs Taxanes. 
METHODS: An experimental, observational, transversal, comparative and multicen-
tric study was done to evaluate the quality of life with the application of two validated 
research instruments: EORTC QLQ-C30 and EORTC QLQ-LC13, to patients with 
NSCLS who previously failed to chemotherapy and currently are treated with Erlo-
tiniband or Taxanes, 24 patients were surveyed for each comparator. A descriptive 
analysis was done using central tendency measurements, frequencies, and a variance 
analysis (ANOVA) to compare quality of life differences with the two different thera-
pies. RESULTS: Global quality of life index for patients in treatment with Erlotinib 
is 0.81 and taxanes 0.62. The consistency in the answers was corroborated using a 
variance analysis (ANOVA), Erlotinib 0.8156 vs Taxanos 0.6281 NOVA Pr  F  
0.0001 Tukey  0.0001. CONCLUSIONS: The use of Erlotinib in patients with 
NSCLS who previously failed to ﬁrst line chemotherapy provides a better quality of 
life and general state of health than therapies based on Taxanes.
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OBJECTIVES: Aim of the present study was to estimate how much a general popula-
tion is willing to pay for a life-year gained (LYG). METHODS: A total of 1500 con-
tingent valuation questionnaires were mailed to a random sample of Slovenian general 
population. Individuals were asked to state their willingness to pay for a new, hypo-
thetical, oncology drug that prolongs survival for 1 year. An ex ante perspective was 
considered, whereby a 30% lifetime risk of getting cancer was presented. Scope test 
was performed by varying beneﬁt and lifetime risk of getting cancer. RESULTS: 
Response rate was 45% (N  680). Average monthly increase in the health insurance 
premium amounted to a12.04 EUR in case individuals were presented with a 30% 
lifetime risk of getting cancer and 1 additional life-year provided by the new drug. On 
average, individuals were willing to pay a9.80 and a16.55 for a drug that provided 3 
additional life-months and 3 additional life-years, respectively. The estimated WTP 
per LYG was a19,921 in case the beneﬁt of the drug was 1 additional year of life. 
This value changed to a61,909 per LYG and a8,917 per LYG for the beneﬁt of 3 
additional months and 3 additional years of life, respectively. CONCLUSIONS: Con-
sidering the beneﬁt of the new drug that poses the smallest constraint on individuals’ 
budget, i.e. 3 additional months of life, incremental cost-effectiveness ratios of up to 
approx. A total of a60,000 per LYG can be regarded as acceptable from the perspec-
tive of the general population.
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OBJECTIVES: Few longitudinal studies have been conducted to characterize the long-
term impact of cancer on employment. The current study used 6 waves (1992, 1994, 
1996, 1998, 2000, 2002) of the Health and Retirement Study to compare patterns of 
employment over time between cancer survivors and non-cancer controls. We exam-
ined overall differences in employment and differences in employment by educational 
attainment. METHODS: Employment status was compared between 989 cancer sur-
vivors who were cancer free in 1992 but developed cancer from 1994–2002 and 9,997 
non-cancer controls. Generalized Estimation Equations were used to compute the odds 
of employment between survivors and controls as a function of time since diagnosis. 
Models were adjusted for age, gender, education, and assessment year. RESULTS: In 
the waves before a cancer diagnosis was reported, cancer survivors and non-cancer 
controls had similar odds of employment. Beginning at the ﬁrst wave a cancer diag-
nosis was reported, cancer survivors had a lower odds of employment relative to 
non-cancer controls (OR  0.61; CI  0.52–0.73). The relative odds of employment 
among survivors plateaued at 2 years (OR  0.67; CI  0.54–0.83) and 4 years (OR 
 0.65; CI  0.49–0.87) after diagnosis and then decreased (OR  0.34; CI  0.23–
0.51) 6 years after diagnosis. The relative odds of employment among cancer survivors 
differed by education. At each wave after a cancer diagnosis was reported, the relative 
odds of employment was higher among cancer survivors with q12 years of education 
compared to survivors with 12 years of education (p  0.02). CONCLUSIONS: 
Cancer has a long term impact on the employment status of survivors. Cancer survi-
vors with lower educational attainment were particularly vulnerable to not working 
after their diagnosis.
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OBJECTIVES: Several new NSCLC agents are expected to enter market over the 
next 10 years. In an era focused on increased cost containment and comparative 
